Tesamorelin

Clinical Test Expectation (Human Subjects)

• Reduction of excess abdominal (visceral) fat

• Commonly referenced in protocols addressing HIV-associated lipodystrophy Tesamorelin is a stabilized synthetic peptide analog of the endogenous hypothalamic peptide Growth Hormone–Releasing Hormone (GHRH). It is designed to stimulate the pituitary gland to increase natural growth hormone secretion, supporting physiologic GH release rather than direct hormone replacement.

Tesamorelin has been clinically indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, a metabolic condition associated with antiretroviral therapy. Lipodystrophy is characterized by fat redistribution, insulin resistance, and altered lipid metabolism.

⸻

Reconstitution & Use Information*

(Catalog reference format)

• Reconstitute by adding 2 mL bacteriostatic water to the vial

• Allow powder to dissolve naturally

• Do not shake the vial

• Solution should be clear before use

Reference draw:

• 30 units (0.3 mL) per administration

• Commonly referenced as once daily, typically before breakfast

• Subcutaneous administration into the abdominal fatty layer

⸻

Vial Longevity

• One vial provides approximately 7 days of use based on the referenced protocol